{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:36Z","timestamp":1753877676262,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>ATTR-CA is an under-reported cause of congestive heart failure (CHF) and cardiac arrhythmias. Heightened clinical suspicion along with a multimodal investigative approach is often required in diagnosing this potentially fatal condition. Tafamidis and inotersen have shown promising results in terms of progression-free survival by ameliorating CHF symptoms and peripheral neuropathies in clinical trials.<\/jats:p>\n               <jats:p>In this case series of five patients, we present three wild-type cardiac amyloidosis (ATTRwt-CA), one familial cardiac amyloidosis (ATTRm-CA) and one primary cardiac (AL-CA). The diagnostic modality was different for each patient. ATTRwt-CA, ATTRm-CA and AL-CA patients received tafamidis, inotersen and chemotherapy with bone marrow stem-cell transplantation, respectively.<\/jats:p>","DOI":"10.1093\/omcr\/omab059","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T11:15:15Z","timestamp":1629112515000},"source":"Crossref","is-referenced-by-count":2,"title":["Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)"],"prefix":"10.1093","volume":"2021","author":[{"given":"Tanvir","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, St. Luke\u2019s Hospital, Chesterfield, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reihaneh C","family":"Moghadam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Luke\u2019s Hospital, Chesterfield, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram V","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Luke\u2019s Hospital, Chesterfield, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig K","family":"Reiss","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Luke\u2019s Hospital, Chesterfield, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"2021081611013994900_ref1","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2021081611013994900_ref2","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","article-title":"Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?","volume":"37","author":"Galat","year":"2016","journal-title":"Eur Heart J"},{"key":"2021081611013994900_ref3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"key":"2021081611013994900_ref4","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"2021081611013994900_ref5","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"42","author":"Sekijima","year":"2011","journal-title":"Hum Pathol"},{"key":"2021081611013994900_ref6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"key":"2021081611013994900_ref7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"2021081611013994900_ref8","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","article-title":"Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure","volume":"67","author":"Sperry","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021081611013994900_ref9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021081611013994900_ref10","article-title":"Safety of inotersen treatment in patients with transthyretin amyloid cardiomyopathy","volume":"73","author":"Dasgupta","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/8\/omab059\/39718110\/omab059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/8\/omab059\/39718110\/omab059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T11:15:26Z","timestamp":1629112526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omab059\/6350627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omab059","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,8,1]]},"article-number":"omab059"}}